$SMTI

The FTC issued a Second Request for more information on MiMedx's (MDXG) acquisition of Sanara (SMTI), delaying the merger beyond the year-end target. SMTI shares fell 5.5%, dropping below their 50-day moving average, while MDXG shares declined 2.8%. The deal, valued at $35 per share, aims to create a larger regenerative medicine company with $400M revenue expected in FY2027.

Sanara MedTech Inc. (SMTI) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously announced, Sanara MedTech Inc., a Texas corporation (the “Company” or “Sanara”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with MiMedx Group, Inc., a Florida corporation (“MiMedx”), and Mustang Merger Sub, Inc., a

Sanara MedTech Inc. (SMTI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders Results of Special Meeting On September 30, 2026, Sanara MedTech Inc., a Texas corporation ( “Sanara”), held a special meeting of shareholders (the “Special Meeting”) to vote on the proposals described in Sanara’s def

Sanara MedTech (SMTI) seeks shareholder approval for a merger with MiMedx. Shareholders will receive $33.00 in cash plus 0.4735 MiMedx shares per Sanara share, valued at roughly $35 per share. The merger requires shareholder approval at a September 30 meeting, with key shareholders already committing their votes in favor.

Sanara MedTech (SMTI) agreed to be acquired by MiMedx Group. The deal, announced on July 29, 2026, is expected to close by year-end, subject to regulatory approvals and other conditions. Both companies will operate independently until the transaction is finalized.

Sanara MedTech Inc. (SMTI) reported Q2 adjusted EPS of $0.05, above the Zacks Consensus Estimate of $0.02, compared with a year-ago loss of $0.23. Revenue was $28.14 million, down from $25.83 million a year earlier, and 4.3% below consensus. For the next quarter, consensus calls for EPS of $0.06 on $30.4 million revenue.

Sanara MedTech (NASDAQ: SMTI) reported Q2 EPS of $(0.05), missing the $0.02 consensus, and sales of $28.137 million, up 8.93% YoY but below the $28.950 million estimate. The article also says Kahn Swick & Foti opened an investigation into SMTI’s proposed acquisition by MiMedx (NASDAQ: MDXG), valuing the deal at about $350 million ($35.00 per SMTI share).

Sanara MedTech Inc. (SMTI) reported Q2 2026 revenue up 9% to $28.1M, driven by soft tissue repair products, with gross margin at 93%. Adjusted EBITDA increased to $5.0M, but higher SG&A and interest contributed to a $0.4M net loss. The company also announced a pending merger with MiMedx Group and reorganized into a single surgical segment.

Sanara MedTech Inc. reported Q2 2026 revenue of $28.14M, up 9.1% year over year from $25.80M. Net loss attributable to shareholders was $0.45M, versus $2.01M a year earlier, and diluted EPS was $(0.05) versus $(0.23). The company cited product sales growth and updates including a Vizient contract and a merger agreement with MiMedx, per its 10-Q.

MiMedx Group (Nasdaq: MDXG) filed an 8-K/A amending its July 29, 2026 report to correct Sanara and MiMedx termination fee amounts. It also describes a merger where Sanara shareholders receive $33.00 cash per share plus 0.4735 shares of MiMedx common stock. MiMedx will issue stock and file an S-4.